Business
Ludwig Enterprises Announces Publication of ASCO Abstract Detailing Novel Non-Invasive mRNA Signals that Scan for Breast Cancer
Ludwig Enterprises Announces Publication of ASCO Abstract Detailing Novel Non-Invasive mRNA Signals that Scan for Breast Cancer.
About this update from Ludwig Enterprises, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Ludwig Enterprises Announces Publication of ASCO Abstract Detailing Novel Non-Invasive mRNA Signals that Scan for Breast Cancer\r\n \r\n \r\n\r\n\r\nLudwig Enterprises Announces Publication of ASCO Abstract Detailing Novel Non-Invasive mRNA Signals that Scan for Breast Cancer\r\n\r\n\r\n\r\n\r\n\r\nMIAMI, FL / ACCESS Newswire / May 29, 2025 / Ludwig Enterprises (LUDG) today announced the publication of an abstract on the American Society of Clinical Oncology (ASCO) website in connection with the ASCO 2025 Annual Meeting, previously under embargo, detailing a novel, non-invasive scanning test for breast cancer. The research combines the analysis of messenger RNA (mRNA) from non-invasively collected buccal (cheek) cells with machine learning algorithms.\r\n The abstract, titled \"Non-invasively-collected buccal cell mRNA reveals novel breast cancer signal,\" highlights the potential of this approach to screen for breast cancer. Breast cancer remains the most frequently diagnosed cancer globally. While DNA genetic testing is widely used, mRNA analysis can offer complementary diagnostic insights, particularly concerning inflammatory pathways linked to cancer development. The study underscores that intercellular mRNA communication is a key characteristic of chronic inflammation associated with cancer development.\r\n \"Ludwig Enterprises is pleased to now share these encouraging findings with the broader scientific community and the public, following the lifting of the ASCO embargo,\" said Marvin S. Hausman, MD, Chief Science Officer at Ludwig Enterprises. \"This research represents a potential step forward in developing less invasive screening options that could aid in the earlier detection of breast cancer.\"\r\n Study Highlights:\r\n \r\n METHODS Buccal cheek swab samples were collected non-invasively from breast cancer patients and controls across 40 U.S. clinical centers, and a custom microarray chip was developed to analyze 48 mRNA-based cytokine biomarkers, selected for their association with inflammatory pathways and cancer development. Next-generation sequencing was performed using Thermo Fisher Genestudio S-5 following cDNA target amplification. We then used these data to train a linear support vector machine to classify subjects with respect to their cancer status. We were particularly interested in iden...